Last reviewed · How we verify

Placebo to ZOSTAVAX™ — Competitive Intelligence Brief

Placebo to ZOSTAVAX™ (Placebo to ZOSTAVAX™) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine (live attenuated). Area: Immunology / Infectious Disease.

phase 3 Vaccine (live attenuated) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Placebo to ZOSTAVAX™ (Placebo to ZOSTAVAX™) — Merck Sharp & Dohme LLC. This is a placebo control arm in a clinical trial comparing against ZOSTAVAX, a live attenuated varicella-zoster virus vaccine designed to prevent herpes zoster (shingles) in older adults.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo to ZOSTAVAX™ TARGET Placebo to ZOSTAVAX™ Merck Sharp & Dohme LLC phase 3 Vaccine (live attenuated)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vaccine (live attenuated) class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to ZOSTAVAX™ — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-zostavax. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: